Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203473 · ClinicalTrials.gov registry record · Phase 2
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
A Phase 2 study of Renal Cancer, sponsored by Toni Choueiri, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 8
- Study locations
NCT03203473 is a Phase 2 study of Renal Cancer that is active but no longer recruiting, run by Toni Choueiri, MD. The registered enrollment target is 85 participants, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (86% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT03203473, a Phase 2 study of Renal Cancer, is active but no longer recruiting, sponsored by Toni Choueiri, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (8)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
California
- University of California, San Diego Moores Cancer Center - La Jolla
Illinois
- University of Chicago Medical Center - Chicago
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Rhode Island
- Lifespan Comprehensve Cancer Center - Providence
Utah
- University of Utah, Huntsman Cancer Center - Salt Lake City
Wisconsin
- Unviersity of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2026-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03203473
The ClinicalTrials.gov registry entry for NCT03203473 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Toni Choueiri, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03203473 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03203473 about?
NCT03203473 is a clinical study titled "Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)". This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
What is the current status of trial NCT03203473?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2017-10-26. Estimated completion is 2026-06-28.
What conditions does trial NCT03203473 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT03203473?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03203473?
This trial is sponsored by Toni Choueiri, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03203473 being conducted?
This trial has 8 study locations across California, Illinois, Massachusetts, North Carolina, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
ACTIVE NOT RECRUITING · Phase 2
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.